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Abstract 
Aims: Acute ischemic mitral regurgitation (MR) is seen in patients with myocardial infarction and is associated with 
increased morbidity and mortality. The optimal treatment strategy of this condition however, is not well established. 
The aim of this manuscript is to conduct a systematic review of the medical literature to assess the relative benefits 
and harms of mitral valve surgery with medical therapy versus medical management alone for patients with acute 
ischemic MR of at least moderate severity.
Methods: We performed a literature search in MEDLINE, Embase.com, and Cochrane Central Register of Controlled 
Trials. We restricted the search to randomized clinical trials comparing surgical to medical management of acute 
ischemic MR. Exclusion criteria included non-randomized trials, trials enrolling patients with non-ischemic MR, and tri-
als excluding acute ischemic MR. The primary outcomes were short-term and long term mortality. Two reviewers (WA, 
WA) screened titles and abstracts of identified citations independently and in duplicate using calibration exercises and 
standardized screening forms.
Results: The search strategy identified 887 citations (137 were duplicates and removed). Of the 750 titles, 709 were 
excluded (519 were non-relevant and 190 were review articles and case reports). Of the 41 remaining abstracts, 37 
were retrospective cohorts and four excluded acute MR, leaving no eligible study for analysis. An ongoing study that 
is being conducted at Southern Illinois University entitled by “Medical Versus Surgical Management of Patients With 
Moderate Mitral Regurgitation Following Percutaneous Coronary Intervention for Myocardial Infarction: A Pilot Pro-
spective Randomized Trial” was identified; however, it was just withdrawn after failing to enroll patients during 4 years.
Conclusion: This is an empty systematic review that identified no published randomized trials for the management 
of acute MR complicating acute MI. The only ongoing randomized study that was identified was just withdrawn after 
failing to enroll patients. There is an urgent need for conducing proper randomized trials in order to guide informed 
decision making in the treatment of acute ischemic MR.
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Background
Acute ischemic mitral regurgitation (MR) is seen in 
patients with myocardial infarction (MI), and is associ-
ated with increased morbidity and mortality. Severe MR 
may occur with a frequency ranging from 0.3 to 3 % [1, 2] 
and is more related to the location of the infarction (more 
commonly seen with inferior MI) rather than the degree 
of infarction [3–7]. Left ventricular remodeling, teth-
ering of the mitral valve leaflets, apical displacement of 
the papillary muscle, and less commonly papillary mus-
cle rupture, contribute to the MR [2, 8–10]. It is gener-
ally accepted that patients with acute ischemic MR due 
to papillary muscle rupture need emergent mitral valve 
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surgery given the exceedingly high mortality rate (up to 
80 %) without intervention [11, 12]. However, in patients 
with acute ischemic MR but without papillary muscle 
rupture, there is no general consensus whether mitral 
valve surgery is warranted or beneficial as opposed to 
medical therapy alone. Subgroup analysis of the SHOCK 
registry (Should we revascularize Occluded Coronar-
ies for cardiogenic shocK) showed that early mitral valve 
replacement was associated with better survival when 
compared to medical therapy alone [6]. However, these 
were observational data with selection bias. Hence, the 
aim of this study was to conduct a systematic review 
of the medical literature to assess the relative benefits 
and harms of mitral valve surgery with medical therapy 
versus medical therapy alone for patients with acute 
ischemic MR.
Methods
We published the research protocol of this systematic 
review online on PROSPERO systematic review database 
prior to the literature search and data extraction. There 
were no modifications between the planned protocol and 
the actual conduct of the review.
Reference URL for published protocol: http://
www.crd.york .ac .uk/PROSPERO/display_record.
asp?ID=CRD42013005843. Search strategy: http://
www.crd.york.ac.uk/PROSPEROFILES/5843_PROTO-
COL_20131106.pdf. (PROSPERO registration number 
CRD42013005843).
Eligibility
Inclusion criteria: The systematic review was designed 
to include only randomized controlled trials. Exclu-
sion criteria: were non-randomized trials, trials enroll-
ing patients with non-ischemic MR such as rheumatic 
or endocarditis, or and trials excluding acute ischemic 
MR. Population: Enrolling patients with acute ischemic 
MR of at least moderate severity, and Intervention: com-
paring control: medical management versus mitral valve 
surgery (annuloplasty, repair, or replacement strategy) 
with respect to mortality outcome. Outcome: The pre-
defined primary outcomes were short-term and long-
term mortality. The secondary outcomes were surgical 
complications, need for surgical intervention, recurrent 
MI, stroke, heart failure, quality of life, and/or length of 
hospitalization.
Literature search
We conducted a literature search in MEDLINE, Embase.
com, and Cochrane Central Register of Controlled Trials 
(CENTRAL). The searches were performed in Cochrane 
on September, 26, 2013; Medline and Embase.com 
searches were conducted on November, 21, 2013. We 
did not apply language or publication period restrictions. 
Additional file  1: Appendix S1 shows the search strate-
gies. We also searched for ongoing research trials about 
the subject in http://www.controlled-trials.com/isrctn/ 
and http://www.clinicaltrials.gov.
The search strategy was drafted by two of the co-authors 
(WA, EA), one of whom (EA) has experience in designing 
search strategies. An information specialist with experi-
ence in systematic reviews (Ms. Aida Farha, head librar-
ian) revised and refined the strategy. We did not subject 
the search strategy to external peer review [13].
Selection, data abstraction, and risk of bias assessment
Two reviewers (WA, WA) screened the titles and 
abstracts of identified citations independently and in 
duplicate. The full texts for citations that were judged by 
at least one of the two reviewers as potentially eligible 
were subsequently retrieved and screened independently. 
The results of the screening process were compared, and 
any disagreement was resolved by either discussion or 
with the help of a third reviewer. Calibration exercises 
were conducted and standardized screening forms based 
on the eligibility criteria were used. We planned for a 
similar approach for data abstraction. We planned to 
assess the risk of bias in each study independently and in 
duplicate using the Cochrane Risk of Bias tool.
Strategy for data synthesis
We assessed the agreement between the two authors for 
the assessment of trial eligibility using kappa statistic. 
Our protocol details the planned analysis plan that we 
did not have the opportunity to use.
Results
The search strategy identified 887 citations (137 were 
duplicates and removed). Of the 750 titles, 709 were 
excluded (519 were non-relevant and 190 were review 
articles and case reports). Of the 41 remaining abstracts, 
37 were retrospective cohorts and four excluded acute 
MR, leaving no eligible study for analysis (Additional 
file  2: Figure S1). Based on our search strategy, we did 
not find any published randomized controlled trial com-
paring outcomes of medical versus surgical treatment 
of acute ischemic MR. However, we found one regis-
tered ongoing randomized controlled trial that is being 
conducted at Southern Illinois University entitled by 
“Medical Versus Surgical Management of Patients With 
Moderate Mitral Regurgitation Following Percutaneous 
Coronary Intervention for Myocardial Infarction: A Pilot 
Prospective Randomized Trial” (ClinicalTrials.gov Iden-
tifier: NCT01156441). Unfortunately, the study has been 
just withdrawn in June 2014 with no enrollment after 
4 years.
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Discussion
Our systematic review serves as the first one in the medi-
cal literature that attempts to summarize the evidence 
from randomized controlled trials comparing medical to 
surgical management of at least acute moderate ischemic 
MR. We found no published randomized controlled clin-
ical trials to answer our inquiry.
The current review is an empty review given no studies 
met the eligibility criteria. Empty reviews are not uncom-
mon and account for 8.7–12 % of Cochrane database of 
systematic reviews [14, 15]. One reason for this review 
being empty is that we limited inclusion to randomized 
clinical trials. The intention was to exclude data from 
non-randomized studies given they are unlikely to be 
reasonably informative for either guideline development 
or clinical decisions.
Indeed, the available non-randomized data on acute 
ischemic MR are based on case reports, case series, and 
registry analyses (Table 1) [6, 9, 16–21]. Typically in these 
studies, patients with higher ejection fraction received 
mitral valve intervention significantly more often than 
patients with lower ejection fraction. This selection bias 
is likely to impact the effect estimates of the outcome of 
interest. As a result, the confidence in the effect estimates 
(i.e., quality of evidence) would be at best low [22]. Also, 
higher quality evidence was expected to be available with 
the publication of the ongoing randomized trial (Clini-
calTrials.gov Identifier: NCT01156441); unfortunately 
the study has been just withdrawn in June 2014 with no 
enrollment after 4 years.
Importantly, our systematic review shows the gap in 
the knowledge about what is the best intervention in the 
treatment of MR following acute myocardial infarction. 
It is our hope that this empty systematic review will help 
stimulate appropriate research, whether well-designed 
prospective observational studies or, ideally, well-
designed and adequately powered, randomized clinical 
trials.
There were several retrospective data on the subject as 
summarized in Table 1. Of the observational data that we 
encountered, one was an analysis of the SHOCK registry 
comparing mortality outcome of severe acute ischemic 
MR treated by mitral valve annuloplasty repair/replace-
ment versus no valve intervention [6]. Between April 
1993 and August 1997, the SHOCK registry enrolled 
1190 patients with suspected cardiogenic shock com-
plicating acute MI. A subgroup analysis of this registry 
included 94 patients with severe MR. Almost half of the 
cohort (N = 43) underwent concomitant coronary artery 
bypass graft with mitral valve surgery (valve replace-
ment was done in most and valve repair was done in six 
patients only), while the remaining patients (N  =  51) 
underwent coronary artery bypass grafting alone with 
medical management of the MR. The in-hospital mortal-
ity rates for valve surgery and non-valve surgery groups 
were 40 and 71  % respectively [6]. The lower mortal-
ity in the group that underwent valve surgery however, 
was predominately driven by a significantly higher left 
ventricular ejection fraction (40 versus 29  %, p =  0.04), 
causing a selection bias. These observational data that 
were identified non-systematically showed some poten-
tial benefit for early surgery given the high mortality 
rate of un-intervened severe MR following acute MI [6]. 
These results must be interpreted with caution however 
Table 1 Summary and  pooled analysis of  non-randomized studies of  patients presenting with  acute ischemic mitral 
regurgitation
EF ejection fraction, MVR mitral valve repair or replacement, N number of patients with acute ischemic mitral regurgitation, NYHA New York Heart Association
# Half of patients had left ventricular systolic dysfunction; (–), not applicable or no patients enrolled in that arm
a These is not cumulative mortality. To get cumulative mortality, add up the numbers where applicable
b Mixed studies including patients with papillary muscle rupture






MVR No MVR MVR No MVR MVR No MVR
Nishimura [16] Case series 1986 7 57 100 49 0/7 (–) 3/7 (–) 1/7 (–)
Kishon [17]b Retrospective 1992 22 68 6/22 (–) (–) (–) 6/22 (–)
Tcheng [9] Retrospective 1992 50 68 35 (–) 16/50 (–) 25/50 (–) (–)
Gillinov [18] Retrospective 2001 95 7/95 (–) 6/95 (–) 74/95 (–)
Minami [19]b Retrospective 2004 6 100 57 2/6 (–) (–) (–) (–) (–)
Russo [20]b Prospective 2008 54 70 98 56 2/54 (–) (–) (–) (–) (–)
Lorusso [21]b Retrospective 2008 126 62 66 # 34/126 (–) (–) (–) 8/126 (–)
Thompson [6] Prospective 2009 94 71 100 37 17/43 36/51 (–) (–) (–) (–)
Pooled 454 67 91 42 68/353 52/101 9/102 25/50 89/252 (–)
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Another multicenter retrospective study evaluated the 
postoperative outcome of emergency surgery for acute 
severe MR [21]. Of 279 total patients enrolled, 126 (45 %) 
had an acute MI and did worse than those without MI. 
On multivariable analysis, associated coronary artery 
disease and acute MI were independent predictors of 
increased short-term and long-term mortality. The type 
of mitral valve surgery (repair versus replacement), how-
ever did not influence the outcomes [21].
When looking at the data of the non-randomized stud-
ies (Table  1), one could notice the mixed cohorts that 
included patients with papillary muscle rupture versus 
leaflet tethering. These are totally different cohorts; yet, 
the reported outcomes are combined and pooled for all 
patients. Furthermore, the studies were of small sam-
ple size, most of them involving only one treatment arm 
(most often mitral valve replacement) which makes any 
possibility of fair comparison of treatment strategy to 
outcomes almost impossible. In addition, the cohorts 
included a very high prevalence of patients with car-
diogenic shock and already depressed left ventricular 
systolic function. Pooling the numbers of all the studies 
did show a significantly lower in-hospital (<30 days) and 
1–12  months mortality for the registry of patients that 
underwent MVR (68/353 versus 51/101 for in-hospital 
mortality, and 9/102 versus 25/50 for 1–12 months mor-
tality, respectively) (Table  1). However these numbers 
must be interpreted very cautiously due to the inhomo-
geneity of the cohorts, study designs and selection bias.
Implications for practice
In absence of robust data, the management of acute 
ischemic MR mostly remains based on expert opinion. 
Nowadays at least, the standards of management involve 
the early identification of MR during acute MI, and the 
differentiation of whether there is papillary or chordal 
disruption or not. It is clinically relevant to differentiate 
papillary muscle ischemia from papillary muscle/chordal 
rupture, since the former might be corrected by revas-
cularization alone, hence sparing the patient the added 
risk of mitral valve repair or replacement. Indeed, obser-
vational data suggested that acute ischemic MR without 
papillary muscle rupture may be treated with coronary 
angioplasty; the 3  year survival of coronary interven-
tion group was 70.2 versus 45.6 % in medical group [23]. 
Figure  1 is a proposed algorithm that summarizes a 
potential approach in the management of patients with 
acute ischemic MR.
Papillary muscle rupture, on the other hand, is an unu-
sual cause of ischemic MR occurring in less than 0.1 % of 
patients [24]. When present, it carries a poor prognosis 
with mortality rates reaching 95  % following MI if left 
without surgical intervention, and with 70  % of death 
occurring within the first 24  h [11, 25]. Other observa-
tional data studies showed that the mortality rate is high 
regardless of valve surgery; it appears to be that these 
patients are at an already advanced stage where inter-
vention may be too late whenever shock occurs [7]. Data 
from a larger and more recent study, however, showed 
that there has been considerable decrease in periopera-
tive mortality across decades (after 1990 as compared to 
prior to 1990) for patients with acute MR secondary to 
papillary muscle rupture undergoing mitral valve surgery, 
particularly when concomitant coronary artery bypass 
graft is performed (odds ratio 0.18; 95  % confidence 
interval 0.04–0.83) [20]. Also, the long term survival was 
similar to those who had an MI without papillary muscle 
rupture [20].
Furthermore, Chevalier et  al. evaluated the predictors 
of increased perioperative mortality of 55 consecutive 
patients with acute MR (45  % papillary muscle rupture, 
22 % partial rupture, and 33 % papillary muscle dysfunc-
tion) post MI undergoing mitral valve surgery (94 % valve 
replacement). Although the perioperative mortality was 
high, it was significantly reduced when concomitant cor-
onary artery bypass graft was performed (34 versus 9 %, 
p = 0.02) [26].
In patients presenting with acute ischemic MR, those 
with papillary muscle rupture warrant emergent mitral 
valve repair/replacement, while those with papillary 
muscle dysfunction or leaflet tethering might have sig-
nificant improvement in the degree of MR after coronary 
revascularization and optimal medical therapy (Fig.  1). 
The role of intra-operative transesophageal echocardio-
gram in guiding whether MVR is needed as an adjunct 
to coronary revascularization in such situation seems jus-
tified, although there is no consensus on such approach 
that varies with different clinical practices.
Limitations
A major limitation is the lack of RCT ending up with an 
empty systematic review. Furthermore, we have lumped 
several types of acute ischemic MR (such as papillary 
muscle rupture, apical tethering) in the search. While 
these subtypes of acute MR behave completely and 
require a different therapeutic approach and there-
fore cannot be lumped together, we opted to include 
any kind of acute ischemic MR in the search to avoid 
exclusion of studies with such subgroups. It was our 
intention to analyze the outcomes of each type of acute 
MR differently; unfortunately, there were no RCT that 
met our inclusion criteria to start with. Furthermore, 
it was kind of expected to have limited RCT given the 
borderline ethical justification one might raise in per-
forming such randomized study. While attempting to 
do pooled analysis of the non-RCT that were found, we 
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were limited by the heterogeneity of the outcomes and 
cohorts that prevented any meaningful large scale data 
pooling.
Conclusion
Based on our systematic review we conclude that there 
is a lack of randomized data comparing the clinical out-
comes of medical management versus mitral valve sur-
gery in patients with acute MR of at least moderate 
severity. In absence of randomized controlled trials, it is 
hard to make a solid informed decision about the optimal 
management of acute severe ischemic MR in the absence 
of papillary muscle rupture, and the treatment remains 
to be based on expert opinion and physician expertise. 
Medical management in such situation might be rea-
sonable if the degree of MR is less than severe or if there 
high suspicion of improvement and reversibility of the 
MR with coronary revascularization. The withdrawal of 
the randomized trial “Medical Versus Surgical Manage-
ment of Patients With Moderate Mitral Regurgitation 
Following Percutaneous Coronary Intervention for Myo-
cardial Infarction” due to failure to enroll patients was 
disappointing. It is our hope that this empty systematic 
review will help stimulate appropriate research, whether 
well-designed prospective observational studies or, ide-
ally, well-designed and adequately powered, randomized 
clinical trials.
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